Abstract
Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.
| Original language | English |
|---|---|
| Pages (from-to) | 192-198 |
| Number of pages | 7 |
| Journal | Journal of Clinical Gastroenterology |
| Volume | 15 |
| Issue number | 3 |
| Publication status | Published - 1992 |
Fingerprint
Keywords
- Drug resistance
- Histamine H2-receptor blockers
- Omeprazole
- Ranitidine
- Reflux esophagitis
ASJC Scopus subject areas
- Gastroenterology
Cite this
Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine. / Porro, Gabriele Bianchi; Pace, Fabio; Peracchia, Alberto; Bonavina, Luigi; Vigneri, Sergio; Scialabba, Anna; Franceschi, Massimo.
In: Journal of Clinical Gastroenterology, Vol. 15, No. 3, 1992, p. 192-198.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Short-term treatment of refractory reflux esophagitis with different doses of omeprazole or ranitidine
AU - Porro, Gabriele Bianchi
AU - Pace, Fabio
AU - Peracchia, Alberto
AU - Bonavina, Luigi
AU - Vigneri, Sergio
AU - Scialabba, Anna
AU - Franceschi, Massimo
PY - 1992
Y1 - 1992
N2 - Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.
AB - Sixty patients who presented with erosive/ulcerative refractory reflux esophagitis were randomized to receive a 4− to 8-week treatment with omeprazole 20 mg daily, or ranitidine 150 mg twice daily. Patients not healed after treatment were given the same drugs at doubled doses for a second period of equal duration. Patients still unhealed after this received open treatment with omeprazole 20 mg twice daily for a third period of 4 to 8 weeks. Endoscopic assessment and clinical and laboratory evaluation were performed every 4 weeks until there was complete esophageal mucosal repair. After 4 weeks, complete healing was observed in 50% of patients on omeprazole 20 mg daily, compared with 20.7% on ranitidine 150 mg twice per day (p <0.01). After 8 weeks, the figures were 79.3% versus 34.5% (p <0.5). With doubled doses after 4 weeks, complete healing was achieved in 96.6% of patients on omeprazole 40 mg daily, compared with 64.2% on ranitidine 300 mg twice per day (p <0.05). The eight still “refractory” patients (one omeprazole, seven ranitidine) healed completely with 8 more weeks of omeprazole 20 mg twice daily. Patients treated with omeprazole experienced faster relief of heartburn, which disappeared in 60% of patients after 4 weeks, as compared to 21% of patients treated with ranitidine (p <0.006). Apart from the mode of treatment, the only factor that proved to be related to healing at multivariate analysis was the pretreatment severity of gastroesophageal reflux, as measured by esophageal pH monitoring. Our study confirms that omeprazole, even at a low dosage, is the choice for refractory reflux esophagitis.
KW - Drug resistance
KW - Histamine H2-receptor blockers
KW - Omeprazole
KW - Ranitidine
KW - Reflux esophagitis
UR - http://www.scopus.com/inward/record.url?scp=0026656870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026656870&partnerID=8YFLogxK
M3 - Article
VL - 15
SP - 192
EP - 198
JO - Journal of Clinical Gastroenterology
JF - Journal of Clinical Gastroenterology
SN - 0192-0790
IS - 3
ER -